(Total Views: 401)
Posted On: 05/28/2018 7:10:07 PM
Post# of 72436
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Let me get this straight. There are 4,000,000 migraine sufferers in the USA that have approx.15 migraine days a month.
So this newly approved drug reduces that number from 15 to 13/14 days. That's about a 10% reduction and it sells for $7,000 a year and is a monthly shot.
Oh and don't take it if you are pregnant or about to become pregnant because they don't know what will happen.
B-OM on the other hand prevents SOM in 40% of chemo-radiation patients,delays onset of SOM,reduces # of days of SOM and is SAFE!
Now these are meaningful statistics and warrant BTD/compassion use ASAP!!!!!!
Wake up FDA!!!!!! Push B-OM through your red tape.
The Food and Drug Administration recent approval of Aimovig, a new preventative treatment against migraines, came as good news for the millions in the United States who suffer from the debilitating headaches. It’s the first approval for a new group of drugs that block a particular molecule that is elevated during migraine, designed to reduce the frequency and severity of migraine attacks.
Most drugs available today reduce migraine symptoms, but Aimovig aims to stop them from happening as frequently. In three clinical studies, patients taking the drug had one or two fewer headache days per month than those taking a placebo. The drug is delivered as a once-monthly injection, and has a sticker price of $6,900 a year.
So this newly approved drug reduces that number from 15 to 13/14 days. That's about a 10% reduction and it sells for $7,000 a year and is a monthly shot.
Oh and don't take it if you are pregnant or about to become pregnant because they don't know what will happen.
B-OM on the other hand prevents SOM in 40% of chemo-radiation patients,delays onset of SOM,reduces # of days of SOM and is SAFE!
Now these are meaningful statistics and warrant BTD/compassion use ASAP!!!!!!
Wake up FDA!!!!!! Push B-OM through your red tape.
The Food and Drug Administration recent approval of Aimovig, a new preventative treatment against migraines, came as good news for the millions in the United States who suffer from the debilitating headaches. It’s the first approval for a new group of drugs that block a particular molecule that is elevated during migraine, designed to reduce the frequency and severity of migraine attacks.
Most drugs available today reduce migraine symptoms, but Aimovig aims to stop them from happening as frequently. In three clinical studies, patients taking the drug had one or two fewer headache days per month than those taking a placebo. The drug is delivered as a once-monthly injection, and has a sticker price of $6,900 a year.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)